A Multi-Institutional Experience With Robotic Ureteroplasty With Buccal Mucosa Graft: An Updated Analysis of Intermediate-Term Outcomes - 31/12/20
, Matthew Lee a, Helaine Koster b, Randall Lee a, Nathan Cheng b, Min Jun c, Jeremy Slawin c, Lee C. Zhao c, Michael D. Stifelman b, Daniel D. Eun aCollaborative of Reconstructive Robotic Ureteral Surgery (CORRUS)
Riassunto |
OBJECTIVE |
To update our prior multi-institutional experience with robotic ureteroplasty with buccal mucosa graft and analyze our intermediate-term outcomes. Although our previous multi-institutional report provided significant insight into the safety and efficacy associated with robotic ureteroplasty with buccal mucosa graft, it was limited by small patient numbers.
METHODS |
We retrospectively reviewed our multi-institutional database to identify all patients who underwent robotic ureteroplasty with buccal mucosa graft between October 2013 and March 2019 with ≥12 months follow up. Indication for surgery was a complex proximal and/or middle ureteral stricture not amenable to primary excision and anastomosis secondary to stricture length or peri-ureteral fibrosis. Surgical success was defined as the absence of obstructive flank pain and ureteral obstruction on functional imaging.
RESULTS |
Of 54 patients, 43 (79.6 %) patients underwent an onlay, and 11 (20.4%) patients underwent an augmented anastomotic robotic ureteroplasty with buccal mucosa graft. Eighteen of 54 (33.3%) patients previously failed a ureteral reconstruction. The median stricture length was 3.0 (IQR 2.0-4.0, range 1-8) centimeters. There were 3 of 54 (5.6%) major postoperative complications. The median length of stay was 1.0 (IQR 1.0-3.0) day. At a median follow-up of 27.5 (IQR 21.3-38.0) months, 47 of 54 (87.0%) cases were surgically successful. Stricture recurrences were diagnosed ≤2 months postoperatively in 3 of 7 (42.9%) patients, and ≥10 months postoperatively in 4 of 7 (57.1%) patients.
CONCLUSION |
Robotic ureteroplasty with buccal mucosa graft is associated with low peri-operative morbidity and excellent intermediate-term outcomes.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Funding: None. |
|
| Conflicts of Interest: Ziho Lee, Matthew Lee, Helaine Koster, Randall Lee, Nathan Cheng, Min Jun, and Jeremy Slawin have no conflicts of interest or financial ties to disclose. Michael Stifelman is a lecturer for Intuitive Surgical, on the scientific advisory board for CONMED, consultant for VTI Medical, and has an educational agreement with Ethicon. Lee Zhao is a consultant for Intuitive. Daniel Eun is a speaker and consultant, and performs meeting activities and case observation for Intuitive Surgical; partial owner and shareholder for Melzi Corp; consultant for Johnson and Johnson; and receives support for trainees (no personal financials) from Hitachi Healthcare Americas. |
Vol 147
P. 306-310 - gennaio 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
